Kane Biotech Inc.
KNBIF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -69.6% | -93.2% | 227.8% | – |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | -60.3% | -162.6% | 10.3% | -69.3% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -5,874.3% | -705.3% | -269.6% | -760.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -7,146.1% | -1,244.9% | -295.4% | -860.4% |
| EPS Diluted | -0.004 | -0.002 | -0.008 | -0.008 |
| % Growth | -71.4% | 74.1% | -2.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |